Figure 6: Six1 decreases RPL26 expression.

(a) A partial sequence of the p53 3′-UTR indicating that the predicted miR-27a-binding site (bold) is 93-bp away from the sequence in the 3′-UTR required for RPL26 binding (underlined). (b) Western blot analyses performed using whole-cell lysates (WCLs) collected from MCF7 and RKO cells with stable overexpression of Six1. (c) Western blot analysis of WCLs collected from seven PDX samples. (d) Linear regression analyses examining the inverse correlation between Six1 and RPL26 expression in patient tumours obtained from the Curtis breast, Gaedcke colon, Grasso prostate and Selemat lung cancer data sets via Oncomine. (e) RPL26 and Six1 expression in the Ma breast four data set in DCIS or invasive DCIS as compared with matched normal breast tissue via Oncomine. (f) RPL26 and Six1 expression in the Grasso prostate data set comparing primary prostate lesions with metastatic lesions via Oncomine. (e,f) The data are shown as the mean±s.e.m. and P values were calculated using an unpaired two-tailed Student’s T-test.